Research programme: anti-cancer therapeutics - AnHorn Medicines
Latest Information Update: 05 Feb 2024
At a glance
- Originator AnHorn Medicines
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 20 Dec 2023 Reserach programme: KRAS-mutated cancer therapeutics - AnHorn Medicines is available for licensing as of 20 Dec 2023. https://www.anhornmed.com/partnering/
- 20 Dec 2023 Early research in Cancer in Taiwan (unspecified route), prior to December 2023 (AnHorn Medicines pipeline, December 2023)